<DOC>
	<DOCNO>NCT02119338</DOCNO>
	<brief_summary>The investigator propose single-center , non-randomized , single-arm study Barrow Neurological Institute/St . Joseph 's Hospital recurrent glioma . The 5-ALA recurrent glioma study correlate presence fluorescence tumor tissue pathological finding . This do use three cohort dose escalation . The investigator ' hypothesis ( low- high-grade glioma , ) low dose 5-ALA result less false positive fluorescence .</brief_summary>
	<brief_title>5-ALA Recurrent Glioma</brief_title>
	<detailed_description>The goal determine dose 5-ALA promotes low volume residual disease resection recurrent high grade glioma without compromise demarcation recurrent high grade glioma postoperative bed normal tissue . Sub-goals : 1 . To determine impact dose 5-ALA improve volumetric extent resection patient recurrent high grade gliomas 2 . To determine impact dose 5-ALA improve overall survival recurrent high grade glioma patient 3 . To determine impact dose 5-ALA improve progression-free survival recurrent high grade glioma patient 4 . To determine impact dose 5-ALA neurological morbidity recurrent high grade glioma patient . Patients presumed recurrent glioma enter trial . Those recurrent disease receive study drug ( 5-ALA ) one three dose-escalated cohort ( 5 mg/kg ; 10 mg/kg ; 20 mg/kg ) . Intraoperatively , patient undergo resection combine fluorescence microscopy confocal microscopy . Resected tissue specimens correspond presence fluorescence send pathology examination . Postoperatively , patient MRI without contrast within 48 hour surgery . Subsequent analysis patient include assessment primary endpoint ( volume residual disease ) volumetrically quantify tumor surgery use T1-weighted contrast-enhancement . Similarly , volumetric extent resection also measure .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Inclusion Criteria Presumed recurrent glioma Age &gt; 18 year Normal bone marrow function ( WBC &gt; 3000 , Platelets &gt; 100,000 ) Exclusion Criteria Pregnancy History photosensitivity , porphyria , exfoliative dermatitis Hepatic dysfunction last 12 month [ define aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALP ) , bilirubin &gt; 2.5 x normal ] Serum creatinine &gt; 180 Âµmol/L Estimated Glomerular Filtration Rate ( eGFR ) &lt; 60 ml/min/1.73m2 Inability undergo MRI contrast</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>5-ala</keyword>
	<keyword>5-aminolevulinic acid</keyword>
	<keyword>fluorescence-guided surgery</keyword>
	<keyword>glioma</keyword>
	<keyword>astrocytoma</keyword>
	<keyword>glioblastoma</keyword>
	<keyword>oligodendroglioma</keyword>
	<keyword>recurrence glioma</keyword>
</DOC>